Research Topics
Species | DAN contact THEODORESCUSummaryAffiliation: University of Virginia Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinomaHillary L Copp
Department of Urology, University of Virginia, Charlottesville, Virginia, USA
Cancer 107:60-6. 2006....- Radical cystectomy with ileal conduit diversion: early prospective evaluation of the impact of robotic assistanceJonathan J Rhee
Department of Urology, University of Virginia, Charlottesville, VA 22908, USA
BJU Int 98:1059-63. 2006..There was no difference in patient BMI between the groups (P = 0.22). CONCLUSION: The daVinci-assisted cystectomy appears to offer some advantages over standard cystectomy. Larger randomized studies are needed to confirm these findings... - Atypical small acinar proliferation: biopsy artefact or distinct pathological entity?Sarah C Flury
Department of Urology, University of Virginia Health System, Charlottesville, VA, USA
BJU Int 99:780-5. 2007.... - Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosisBehfar Ehdaie
Department of Urology, Box 422, University of Virginia, Charlottesville, Virginia 22908, USA
Expert Rev Anticancer Ther 8:1103-10. 2008.... - Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenograftsL R Karns
1Upstate Biotechnology Inc, Charlottesville, Virginia, USA
BMC Biotechnol 1:11. 2001..The popularity of the ecdysone inducible gene switch system has led us to investigate whether such a system can successfully regulate gene expression in a syngeneic tumor system in vivo... - Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expressionD Theodorescu
Department of Urology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
Int J Cancer 78:775-82. 1998..Our results would seem to corroborate the notion that a high dietary intake of isoflavones is a likely explanation for the decreased incidence of invasive bladder cancer... - Molecular pathogenesis of urothelial bladder cancerD Theodorescu
University of Virginia, Department of Urology, P O Box 800422, Charlottesville, Virginia 22908, USA
Histol Histopathol 18:259-74. 2003..The intent of this review is to provide the reader an overview of our current understanding of this tumor from the standpoint of its molecular biology as related to tumor development and progression... - The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapyTracey Krupski
Department of Urology, University of Virginia Health Sciences Center, Box 422, Charlottesville, VA 22908, USA
Eur Urol 43:467-72. 2003..We sought to determine if data from patients treated with neoadjuvant androgen ablation followed by BT at our institution supported this notion using a cross-sectional study design... - Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancerDan Theodorescu
Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
Clin Cancer Res 10:3800-6. 2004.... - Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysisDan Theodorescu
Department of Molecular Physiology, Mellon Prostate Cancer Institute, University of Virginia, Charlottesville, VA, USA
Lancet Oncol 7:230-40. 2006..We aimed to use mass spectrometry and bioinformatics to define and validate a cancer-specific proteomic pattern... - RhoGDI2: a new metastasis suppressor gene: discovery and clinical translationMichael A Harding
Department of Urology, University of Virginia, Charlottesville, VA 22908, USA
Urol Oncol 25:401-6. 2007..These targets, endothelin-1 and Neuromedin U are excellent potential targets for therapeutic intervention in the metastatic cascade... - Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive surveyJoshua D Hall
Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
Urology 61:402-7. 2003..In addition, by examining post-treatment "surprises," our data will allow the development of improved educational approaches to aid decision making... - Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancerHillary Copp
Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
Urology 65:1146-51. 2005..2 ng/mL criterion. CONCLUSIONS: Trimodality RT offers excellent tumor control in patients with poor prognosis who often relapse early. Longer follow-up will be important to determine whether these results are durable over time... - Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapyNicole Miller
Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
Cancer 103:2499-506. 2005..A longer follow-up period will be needed to verify whether these are predictive of long-term cancer control... - Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cellsPeter C Black
Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 14:1478-86. 2008..The aim of this study was to define molecular markers of response to cetuximab therapy in a panel of urothelial carcinoma cell lines... - Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapyCOURTNEY POLLARD
Department of Molecular Physiology, University of Virginia, Charlottesville, 22908, USA
Am J Pathol 175:1824-30. 2009..Although these predictive results were obtained on tumor tissues, the presence of GGH and DBI in urine serves as a rationale for developing them as urinary markers of clinical outcomes for patients treated with neoadjuvant MVAC... - Src phosphorylation of RhoGDI2 regulates its metastasis suppressor functionYimin Wu
Department of Molecular Physiology, University of Virginia, Charlottesville, VA 22908, USA
Proc Natl Acad Sci U S A 106:5807-12. 2009..Our findings also suggest caution in using Src inhibitors in the hope of delaying progression in patients with bladder cancer... - Pathways of metastasis suppression in bladder cancerNeveen Said
Department of Urology, University of Virginia, Box 800422, Charlottesville, VA 22908, USA
Cancer Metastasis Rev 28:327-33. 2009..In this review, we will discuss the established roles of c-Src and RhoGDI2 in bladder cancer and speculate on their therapeutic relevance... - RhoGDI2 is an invasion and metastasis suppressor gene in human cancerJohn J Gildea
Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
Cancer Res 62:6418-23. 2002..These results indicate that RhoGDI2 is a metastasis suppressor gene, a marker of aggressive human cancer, and a promising target for therapy... - Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of actionDora Bigler
Department of Molecular Physiology and Biological Physics and Cancer Center, University of Virginia, Health Sciences Center, Charlottesville, VA 22908, USA
Oncogene 22:1261-72. 2003.... - Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapyNicole L Miller
Department of Urology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
Cancer 97:1203-10. 2003.... - Surgery or radiation: what is the optimal management for locally advanced prostate cancer?Sophie G Fletcher
Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
Can J Urol 12:58-61; discussion 101-2. 2005..CONCLUSION: The optimal management for patients with locally advanced prostate cancer is unclear. While randomized clinical trials will eventually shed light on this question, interim solutions may provide some answers in the short term... - Complementary and alternative medicine modality use and beliefs among African American prostate cancer survivorsRandy A Jones
School of Nursing, University of Virginia, Charlottesville, VA, USA
Oncol Nurs Forum 34:359-64. 2007..To examine the cultural beliefs and attitudes of African American prostate cancer survivors regarding the use of complementary and alternative medicine (CAM) modalities... - Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancerJae K Lee
Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA
Clin Cancer Res 16:711-8. 2010..Our goal was to compare the performance of four conceptually different predictors in an independent cohort of patients... - Robot-assisted radical cystectomy in the management of bladder cancerJessica L Keim
Paul Mellon Prostate Cancer Institute and Department of Urology, University of Virginia Health Sciences Center, Charlottesville, VA, USA
ScientificWorldJournal 6:2560-5. 2006.... - A strategy for predicting the chemosensitivity of human cancers and its application to drug discoveryJae K Lee
Department of Public Health Sciences, University of Virginia, Charlottesville, VA 22908, USA
Proc Natl Acad Sci U S A 104:13086-91. 2007..Furthermore, we used COXEN for in silico screening of 45,545 compounds and identify an agent with activity against human bladder cancer... - Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancerDmytro M Havaleshko
Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA
Neoplasia 11:1185-93. 2009..These results have significant implications for the use of such tools in personalizing the approach to cancers treated with EGFR-directed targeted therapies... - Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous disseminationSteven Christopher Smith
Department of Molecular Physiology and Biological Physics, University of Virginia Health System, Charlottesville, VA 22908, USA
Am J Pathol 174:371-9. 2009..In summary, LAMC2 is a novel biomarker of bladder cancer metastasis that reflects the propensity of cells to metastasize via either lymphatic or hematogenous routes... - Invasion and metastasis models for studying RhoGDI2 in bladder cancerMatthew D Nitz
Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia, USA
Methods Enzymol 439:219-33. 2008.... - Family interactions among African American prostate cancer survivorsRandy A Jones
School of Nursing, University of Virginia, Charlottesville, VA 22908, USA
Fam Community Health 31:213-20. 2008..Data analysis revealed that support from family members and friends plays an important role in how men cope with their treatment and recovery from prostate cancer... - Integrin agonists as adjuvants in chemotherapy for melanomaMartin A Schwartz
Department of Microbiology, Robert M Berne Cardiovascular Research Center, University of Virginia, 415 Lane Road, Charlottesville, VA 22908, USA
Clin Cancer Res 14:6193-7. 2008..Thus, reduced integrin-dependent adhesion to ECM could mediate therapy resistance. The goal of this study was to test whether stimulation of integrin signaling could increase chemotherapeutic efficacy... - Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomasHelen P Cathro
Department of Pathology, University of Virginia Health System, Charlottesville, 22908, USA
Cancer Immunol Immunother 59:465-72. 2010..The goal of this study was to analyze protein expression of antigen processing machinery (APM) components in bladder carcinoma (BC), and to assess the clinical significance of defects in their expression... - RhoGDI signaling provides targets for cancer therapyMichael A Harding
Department of Urology, University of Virginia, Charlottesville, Virginia, USA
Eur J Cancer 46:1252-9. 2010..Several novel therapeutic strategies are proposed for intervening in RhoGDI signaling, and potential complications arising from their implementation are discussed... - Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasisZhong Wu
Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA
Neoplasia 11:66-76. 2009..Our results suggest a hypothetical model whereby PTEN loss upregulates cell cycle genes such as cdc6 and cyclin E2 that in turn promote metastatic colonization at distant sites... - Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urineDan Theodorescu
Paul Mellon Prostate Cancer Institute, University of Virginia, Charlottesville, VA 22908, USA
Electrophoresis 26:2797-808. 2005..In conclusion, this early pilot study suggests that CE-MS of urine warrants further investigation as a tool that can identify putative biomarkers for CaP... - Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancerEmily B Bradley
Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908-0422, USA
BJU Int 94:1003-9. 2004..Men treated with BTC have a worse QoL... - When is a negative lymph node really negative? Molecular tools for the detection of lymph node metastasis from urological cancerDan Theodorescu
Department of Urology, Molecular Physiology, University of Virginia Health System, Charlottesville, VA 22908-0422, USA
Urol Oncol 22:256-9. 2004 - Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profilingMichael A Harding
Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia 22908, USA
Cancer Res 62:6981-9. 2002.... - Perioperative costs and charges of prostate brachytherapy and prostatectomyAntoine A Makhlouf
Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
Urology 60:656-60. 2002..Without a clear cost advantage of USBT over RP, the choice of therapy should continue to be primarily influenced by tumor characteristics, treatment efficacy, and patient preference... - Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomasChristopher Y Thomas
Department of Hematology and Oncology, UVA HSC, P.O. Box 800716, Charlottesville, VA 22908, USA
World J Urol 24:565-78. 2006 - Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapyPaul D Williams
Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia 22908, USA
Cancer Res 69:8302-9. 2009..Use of such in vitro-based GEMs may provide a robust and generalizable approach to personalized cancer therapy... - The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancerSteven C Smith
Department of Molecular Physiology, University of Virginia, Charlottesville, Virginia 22908, USA
Cancer Res 70:1753-8. 2010.... - Status of robotic cystectomy in 2005Nicole L Miller
Department of Urology, Methodist Hospital Institute for Kidney Stone Disease and Indiana University School of Medicine, 1801 N Senate Blvd, Suite 220, Indianapolis, 46202, USA
World J Urol 24:180-7. 2006..We review the current experience with laparoscopic and robotic radical cystectomy and its role in the treatment of muscle invasive bladder cancer... - Health-related quality of life after prostate brachytherapyNicole L Miller
Department of Urology, University of Virginia, Charlottesville, Virginia, USA
BJU Int 94:487-91. 2004 - Molecular credentialing of rodent bladder carcinogenesis modelsPaul D Williams
Department of Public Health Sciences, Division of Biostatistics, University of Virginia School of Medicine, Charlottesville, VA 22908 0717, USA
Neoplasia 10:838-46. 2008..Finally, we provide a list of genes that are likely candidates for driving this disease process by virtue of their concordant regulation in tumors of all three species... - Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2Brian Titus
Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia 22908, USA
Cancer Res 65:7320-7. 2005..The data also suggest that blockade of the ET-1 axis may prevent lung metastasis, a new therapeutic concept that warrants clinical evaluation... - PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activityJohn J Gildea
Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Box 422, Charlottesville, VA 22908, USA
Oncogene 23:6788-97. 2004.... - Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate modelJill K Slack-Davis
Department of Microbiology, University of Virginia, Charlottesville, Virginia 22908, USA
Mol Cancer Ther 8:2470-7. 2009.... - Rap2 regulates androgen sensitivity in human prostate cancer cellsDora Bigler
Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
Prostate 67:1590-9. 2007..Here we ask if Rap proteins play a role in determining androgen sensitivity of human prostate cancer cells either alone or in the context of an activated Ras... - Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPasesKonstadinos Moissoglu
Robert M Berne Cardiovascular Research Center, University of Virginia, Charlottesville, Virginia 22908, USA
Cancer Res 69:2838-44. 2009..These data show that RhoGDI2 metastasis inhibition works through Rho GTPases but via a mechanism distinct from inhibition of membrane association... - Ras superfamily monomeric G proteins in carcinoma cell motilityGary Oxford
Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA
Cancer Lett 189:117-28. 2003..Novel emerging mechanisms of migration in carcinoma cells involving RhoC and Ral are also discussed... - The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic targetSteven Christopher Smith
Department of Urology, Molecular Physiology, Biological Physics, University of Virginia Health System, Charlottesville, VA 22908, USA
Urol Oncol 27:42-7. 2009..These findings are reviewed here and suggest that Ral GTPases and their downstream pathways constitute key mediators of bladder cancer progression and may include targets for future therapeutic strategies... - Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancerSophie G Fletcher
Department of Urology, University of Virginia Health System, Charlottesville, VA 22908, USA
Int J Radiat Oncol Biol Phys 66:1092-9. 2006..44 (0.26-0.74; p = 0.002). CONCLUSIONS: High-risk prostate cancer patients receiving multimodality radiation therapy (BTC) display apparently superior BFS compared with those receiving surgery (RP) or brachytherapy alone (BTM)... - Permanent interstitial brachytherapy for prostate cancer: a current reviewJeffrey Woolsey
Department of Urology, University of Virginia Health Sciences Center, Box 422, Charlottesville, VA 22908, USA
World J Urol 21:209-19. 2003..Results will be discussed both in terms of cancer control and health-related quality of life endpoints... - The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancerSteven C Smith
Department of Molecular Physiology, University of Virginia, Charlottesville, Virginia, USA
Cancer Res 66:1917-22. 2006..We suggest that these insights may lead to future therapeutic approaches that seek to eliminate CD24 function in cancer cells... - Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)COURTNEY POLLARD
Department of Molecular Physiology, University of Virginia, Charlottesville, VA 22908, USA
Expert Rev Mol Med 12:e10. 2010..Since several of these driving changes are amenable to therapeutic targeting, understanding the signalling events in NMIUC may offer novel approaches to manage the recurrence and progression of this disease... - The role of Ras superfamily proteins in bladder cancer progressionGary Oxford
Department of Urology, University of Virginia Health Sciences Center, Charlottesville, VA, USA
J Urol 170:1987-93. 2003..CONCLUSIONS: The findings discussed offer the hopeful possibility that signaling pathways mediated by Ras superfamily members may offer new opportunities for diagnostic and therapeutic interventions in bladder cancer... - Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?Emily B Smith
Department of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
Cancer 94:2282-7. 2002..Therefore, outcome studies including a biopsy Gleason score from older specimens as a risk variable have a significant chance of being vulnerable to this phenomenon. Based on the authors' data, all such specimens should undergo rereview... - A novel model to identify interaction partners of the PTEN tumor suppressor gene in human bladder cancerMikael Herlevsen
Department of Molecular Physiology, University of Virginia, Charlottesville, VA 22908, USA
Biochem Biophys Res Commun 352:549-55. 2007..In conclusion, using a biologically relevant model system to dissect PTEN tumor suppressor function in human bladder cancer, we identified three molecules important for many cellular functions in complex with PTEN... - Prospective outcomes associated with migration from preoperative to intraoperative planned brachytherapy: a single center reportJeffrey Woolsey
Departments of Urology, University of Virginia Health Sciences Center, Charlottesville, Virginia, USA
J Urol 172:2528-31. 2004..In addition, the approach is not associated with any changes in early postoperative voiding symptoms and, due to only marginally longer operative times, may have a cost advantage by eliminating the preplanning visit and ultrasound... - Cancer incidence after localized therapy for prostate cancerKihyuck Moon
Department of Urology, University of Virginia, Charlottesville, Virginia 22908, USA
Cancer 107:991-8. 2006..It is noteworthy that, to the authors' knowledge, this report shows for the first time that, despite the higher doses of radiation delivered, patients who received radioactive implants had the lowest odds of developing second cancers... - Unusual case of recurrent low-grade invasive and endophytic squamous cell carcinoma of the penisCaroline D Ames
Department of Urology, University of Virginia, Charlottesville, VA, USA
Scand J Urol Nephrol 38:258-9. 2004..We present a case of low-grade yet recurrent and invasive squamous cell carcinoma that may constitute a new biological variant of penile cancer... - Morbidity of modified prophylactic inguinal lymphadenectomy for squamous cell carcinoma of the penisTimothy R Coblentz
Department of Urology, University of Virginia Health Sciences Center, Charlottesville, 22908, USA
J Urol 168:1386-9. 2002..Early followup indicates that the local recurrence rate does not appear to increase compared to similar patients reported on in the literature treated with the classic dissection technique... - Mass spectrometry based proteomics in urine biomarker discoveryDan Theodorescu
Department of Molecular Physiology, University of Virginia, Charlottesville, USA
World J Urol 25:435-43. 2007..The second part summarizes the recent progress in the definition and identification of clinically relevant polypeptide markers... - Expression of ral GTPases, their effectors, and activators in human bladder cancerSteven Christopher Smith
Department of Molecular Physiology, University of Virginia, Charlottesville, Virginia 22908, USA
Clin Cancer Res 13:3803-13. 2007.... - Metastasis: a therapeutic target for cancerPatricia S Steeg
Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Nat Clin Pract Oncol 5:206-19. 2008..Here we discuss the similarity and differences between primary tumors and metastases, pathways controlling the colonization of a distant organ, and incorporation of antimetastatic therapies into clinical testing... - Brachytherapy for prostate cancer: follow-up and management of treatment failuresEric M Horwitz
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Urol Clin North Am 30:737-50, viii-ix. 2003..Finally, a comprehensive review of the management of local recurrence following brachytherapy is offered... - Statistical identification of differentially labeled peptides from liquid chromatography tandem mass spectrometryHyungJun Cho
Department of Statistics, Korea University, Seoul, Korea
Proteomics 7:3681-92. 2007.... - Brachytherapy of prostate cancer after colectomy for colorectal cancer: pilot experiencePanos G Koutrouvelis
URO Radiology Prostate Institute, 8320 Old Courthouse Road, Vienna, Virginia 22182, USA
J Urol 173:82-5; discussion 85-6. 2005..We present a method of brachytherapy for prostate cancer using a 3-dimensional stereotactic system and computerized tomography guidance in patients without a rectum due to previous treatment for colorectal cancer... - Radiation for prostate cancer issueDan Theodorescu
World J Urol 21:189. 2003 - Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approachBrian Nicholson
Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia, USA
Clin Cancer Res 10:8728-34. 2004..Increased necrosis observed in tumors from orchiectomized mice receiving ZD6474 also suggests benefit from combining anti-androgen and anti-VEGF signaling approaches... - The role of Ral A in epidermal growth factor receptor-regulated cell motilityJohn J Gildea
Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
Cancer Res 62:982-5. 2002..This is the first demonstration of an essential role for Ral in EGF-mediated cell motility and its potential contribution to tumor metastasis in human cancer... - Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical applicationCarrie W Rinker-Schaeffer
Section of Urology, Department of Surgery, The University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 12:3882-9. 2006 - Adrenal tumor with caval extension--case report and review of the literatureJohn P Chesson
Department of Urology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
Scand J Urol Nephrol 36:71-3. 2002..Our review suggests that over half of all adrenal lesions with IVC extension will be clinically nonfunctional, including up to 17% of pheochromocytomas... - RalA and RalB: antagonistic relatives in cancer cell migrationGary Oxford
Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
Cancer Res 65:7111-20. 2005..In summary, we present the first demonstration that despite their significant sequence homology, RalA and RalB have nonoverlapping and opposing functions in cancer cell migration but overlapping functions in cell growth... - Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesisChristopher Y Thomas
J Urol 176:1909-10. 2006 - Profiling the evolution of human metastatic bladder cancerBrian E Nicholson
Department of Molecular Physiology and Biological Physics, Division of Biostatistics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
Cancer Res 64:7813-21. 2004.... - Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapyRichard K Valicenti
Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
J Urol 168:2499-504; discussion 2504. 2002..Longer followup will be needed to evaluate this hypothesis... - Isolation and identification of potential urinary microparticle biomarkers of bladder cancerDavid M Smalley
Mellon Medical Biomarker Discovery Laboratory, W M Keck Laboratory for Mass Spectrometry, Department of Urology, University of Virginia, Charlottesville, Virginia 22908, USA
J Proteome Res 7:2088-96. 2008..Further studies will be needed to validate these potential biomarkers...
Research Grants
- Understanding the RhoGDI2 metastasis suppressor geneDAN contact THEODORESCU; Fiscal Year: 2010..The goal of this project is to understand the mechanisms that underlie lung metastasis in human bladder cancer and use this knowledge to predict and treat this lethal condition in patients. ..
- Signaling and Progression in Prostate CancerDan Theodorescu; Fiscal Year: 2007..abstract_text> ..
- Ral in human bladder cancer progressionDan Theodorescu; Fiscal Year: 2007..abstract_text> ..
- ENDOTHELIAL GROWTH FACTOR IN PROSTATE CANCER METASTASISDan Theodorescu; Fiscal Year: 2005..abstract_text> ..
- RAl GTPases and partners in human bladder cancer metastasisDan Theodorescu; Fiscal Year: 2010..The goal of this project is to understand the mechanisms that underlie lung metastasis in human bladder cancer and use this knowledge to predict and treat this condition in patients. ..